Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Green light for two new medicines in the EU

Written by | 22 Jun 2023 | Pharmacology

The European Medicines Agency (EMA) has approved two new medicines at its May meeting. This brings to 30, the number of products given the green light by the EMA’s human medicine committee (CHMP) in 2023.

The new products are:

  • Pylclari (piflufolastat (18F)), intended for the diagnosis of prostate cancer.
  • Ztalmy (ganaxolone) for the treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 deficiency disorder, a genetic disorder defined by seizures beginning in infancy.

The committee also recommended two extensions of indication for medicines that are already authorised in the EU: Opdivo and Sogroya.

Following a re-examination, the CHMP confirmed its original recommendation to refuse the granting of a marketing authorisation for Sohonos (palovarotene). This medicine was intended to treat fibrodysplasia ossificans progressiva, a rare genetic disease that causes extra bone to form in places outside the skeleton, such as in joints, muscles, tendons and ligaments, leading to progressively decreasing mobility and other severe impairments.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.